A lung adenocarcinoma patient with ROS1 fusion and NBN germline mutation achieves long progression-free survival from sintilimab combined with niraparib after failure of ROS1 inhibitors: a case report

Saved in:
Bibliographic Details
Published in:Annals of translational medicine 2022-08, Vol.10 (16), p.912-912
Main Authors: Xu, Fangye, Xiao, Chunmei, Sun, Weijie, He, Yuange, Chalela, Roberto, Masuda, Ken, Ulivi, Paola, Shen, Kai, Shao, Qianwen, Xu, Jiali, Liu, Lianke
Format: Article
Language:English
Subjects:
iMDT Corner
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:2305-5839
2305-5839
DOI:10.21037/atm-22-3582